Modulating CAR-T cell exhaustion and fitness in acute myeloid leukemia: mechanistic metabolic and microenvironmental strategies
Chimeric antigen receptor (CAR) T-cell therapy has achieved transformative outcomes in B-cell malignancies but remains limited in acute myeloid leukemia (AML), where antigenic heterogeneity, a suppressive myeloid-driven microenvironment, and a metabolically restrictive bone marrow niche collectively...
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2026-06-01
|
| Ráidu: | Frontiers in Immunology |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1863485/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
